1
|
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.
|
J Clin Oncol
|
2004
|
3.40
|
2
|
Controlling tumor growth by modulating endogenous production of reactive oxygen species.
|
Cancer Res
|
2005
|
3.12
|
3
|
Cost effectiveness of integrated medicine in patients with cancer receiving anticancer chemotherapy.
|
J Oncol Pract
|
2012
|
1.50
|
4
|
Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo.
|
Mol Cancer Ther
|
2012
|
1.13
|
5
|
Effect of integrated palliative care on the quality of end-of-life care: retrospective analysis of 521 cancer patients.
|
BMJ Support Palliat Care
|
2012
|
1.09
|
6
|
An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity.
|
Oncologist
|
2011
|
1.08
|
7
|
Arsenic trioxide exerts antitumor activity through regulatory T cell depletion mediated by oxidative stress in a murine model of colon cancer.
|
J Immunol
|
2012
|
1.02
|
8
|
Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?
|
J Natl Cancer Inst
|
2007
|
0.96
|
9
|
Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence.
|
Gynecol Oncol
|
2007
|
0.93
|
10
|
Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.
|
Target Oncol
|
2012
|
0.91
|
11
|
Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir.
|
J Clin Invest
|
2013
|
0.90
|
12
|
Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy.
|
Anticancer Drugs
|
2005
|
0.84
|
13
|
Stimulation of angiogenesis resulting from cooperation between macrophages and MDA-MB-231 breast cancer cells: proposed molecular mechanism and effect of tetrathiomolybdate.
|
BMC Cancer
|
2010
|
0.83
|
14
|
Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
|
Anticancer Drugs
|
2009
|
0.83
|
15
|
Bystander effect of vinorelbine alters antitumor immune response.
|
Int J Cancer
|
2011
|
0.82
|
16
|
Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.
|
Lung Cancer
|
2012
|
0.81
|
17
|
Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities.
|
Anticancer Drugs
|
2005
|
0.81
|
18
|
Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.
|
Expert Opin Drug Metab Toxicol
|
2015
|
0.80
|
19
|
Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma.
|
Cancer Chemother Pharmacol
|
2010
|
0.79
|
20
|
CYP3A4/5 and pharmacogenetics in patients with sarcoma.
|
Lancet Oncol
|
2007
|
0.78
|
21
|
Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials.
|
Clin Cancer Res
|
2004
|
0.78
|
22
|
[Use of antioxidant and other complementary medicine by patients treated by antitumor chemotherapy: a prospective study].
|
Bull Cancer
|
2011
|
0.78
|
23
|
Nutritional status is superior to the ECOG performance status in predicting the dose-intensity of the GEMOX chemotherapy regimen in patients with advanced cancer.
|
Nutr Cancer
|
2013
|
0.78
|
24
|
Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients.
|
Invest New Drugs
|
2011
|
0.77
|
25
|
Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
|
Cancer Chemother Pharmacol
|
2009
|
0.77
|
26
|
A new strategy to target regulatory T cells in solid tumors.
|
Oncoimmunology
|
2013
|
0.77
|
27
|
An original administration of ifosfamide given once every other week: a clinical and pharmacological study.
|
Anticancer Drugs
|
2008
|
0.76
|
28
|
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
|
Invest New Drugs
|
2006
|
0.76
|
29
|
A Real-Life Experience of Bevacizumab in Elderly Women With Advanced Ovarian Carcinoma.
|
Int J Gynecol Cancer
|
2016
|
0.76
|
30
|
A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial.
|
Support Care Cancer
|
2013
|
0.75
|
31
|
Association between high antitumor activity of oxaliplatin and cyclophosphamide and constitutional GSTM1 homozygous deletion in an advanced ovarian cancer patient.
|
Chemotherapy
|
2014
|
0.75
|
32
|
Primitive neuroectodermal tumor of the myometrium with cardio-vascular symptoms.
|
Gynecol Oncol
|
2007
|
0.75
|
33
|
A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
|
Breast Cancer Res Treat
|
2011
|
0.75
|
34
|
[Role of antioxidant complements and supplements in oncology in addition to an equilibrate regimen: a systematic review].
|
Bull Cancer
|
2009
|
0.75
|
35
|
[Fruits, vegetables . . . but not antioxidant].
|
Bull Cancer
|
2009
|
0.75
|
36
|
[Ovarian immature teratoma during pregnancy].
|
Presse Med
|
2010
|
0.75
|
37
|
Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovary.
|
Int J Gynecol Cancer
|
2014
|
0.75
|
38
|
Is thrombotic microangiopathy associated with antitumoral activity?
|
Gynecol Oncol
|
2006
|
0.75
|